Genes & biomarkers
FGFR2 fusions and rearrangements
FGFR2 · fusion / rearrangement
FGFR2 fusions/rearrangements are targets in some bile duct cancers.
Sources checked · Introductory guide
On this page
What does this result mean?
FGFR2 encodes a growth-signaling receptor. Structural changes, including joining to another gene, can be important in bile duct cancer.[1]
How does it connect to treatment?
Pemigatinib is used in selected previously treated bile duct cancers with FGFR2 fusions/rearrangements. Other FGFR2 variants or changes in another FGFR gene do not automatically qualify.[2]
What should I check in my report?
Check whether a fusion/rearrangement was confirmed, rather than amplification or a VUS. Review operability and previous treatment as well.
Questions for your care team
- Is my FGFR2 finding a qualifying fusion/rearrangement for bile duct treatment?
- Which treatments or trials fit my cancer type, stage and previous treatment?
Sources and scope
Source documents are in English.
Entries summarize and translate linked official public sources. The source-check date records when those sources were checked; it does not indicate a clinician’s review.
General information based on official public sources. This is not a complete list of uses or side effects. Individual treatment decisions require your care team and current source documents. US-source uses do not establish local approval or reimbursement.